Law360, New York ( June 28, 2012, 1:24 PM EDT) -- For a decade now, courts have been grappling with whether so-called "reverse payments" by pioneer pharmaceutical manufacturers to generic competitors in settlement of patent infringement litigation violate the antitrust laws, and with how the competitive effects of reverse-payment settlements should be analyzed. The year 2003 saw a spate of opinions on reverse-payment settlements by circuit courts, the Federal Trade Commission, and noted antitrust scholar Judge Richard Posner (sitting by designation in federal district court).[1] ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.